Solid Biosciences Reports Increased Assets Amid Ongoing Losses

Solid Biosciences ( (SLDB) ) has released its Q2 earnings. Here is a breakdown of the information Solid Biosciences presented to its investors.

Solid Biosciences Inc. is a life sciences company focused on developing gene therapy candidates for neuromuscular and cardiac diseases, including Duchenne muscular dystrophy and Friedreich’s ataxia. In its latest earnings report for the quarter ending June 30, 2025, Solid Biosciences highlighted a significant increase in cash and cash equivalents, reaching $138.9 million, compared to $80.2 million at the end of 2024. The company’s total assets rose to $308.3 million from $188.7 million, driven by successful public offerings and strategic financing activities. Despite the increase in assets, the company reported a net loss of $39.5 million for the quarter, reflecting ongoing investments in research and development, which accounted for $32.4 million of expenses. Looking ahead, Solid Biosciences remains committed to advancing its pipeline of gene therapy candidates, with management expressing confidence in their financial position to support operations for at least the next twelve months.